RotaTeq Vaccine Description
RotaTeq is a live, oral pentavalent vaccine that contains 5 reassortant viruses.
Four reassortant rotaviruses express one of the outer capsid proteins (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (serotype P7) from the bovine rotavirus parent strain.
The fifth reassortant virus expresses the attachment protein, P1A (genotype P), referred to as serotype P1A, from the human rotavirus parent strain and the outer capsid protein of serotype G6 from the bovine rotavirus parent strain.
RotaTeq was extensively tested and was approved by the US Food and Drug Administration (FDA) in February 2006.
RotaTeq Vaccine Indication
RotaTeq is indicated to prevent rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9.
RotaTeq is approved for use in infants 6 weeks to 32 weeks of age.
RotaTeq Vaccine Dosage
The vaccination series is administered as an oral 3-dose series to infants between the ages of 6 to 32 weeks.
The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
The third dose should not be given after 32 weeks of age.
RotaTeq Vaccine News
January 20, 2022 - In a Lancet article they reported on a study that showed RV3-BB was well tolerated and immunogenic when co-administered with Expanded Programme on Immunisation vaccines in a neonatal or infant schedule.
May 10, 2021 - A study published by JAMA Pediatrics found the high protection and low risk of serious adverse events for rotavirus vaccines in children who were fully vaccinated emphasized the importance of worldwide rotavirus vaccinations. This study's findings from a meta-analysis revealed that RotaTeq vaccinations reduced rotavirus gastroenteritis in children younger than 5 years by 63.6%.
April 29, 2021 - Merck reported RotaTeq vaccine sales decreased 29% last year.
RotaTeq Clinical Trials
RotaTeq was US FDA approved in 2006. This rotavirus vaccine continues to be challenged in clinical trials today.